Equities research analysts forecast that Invuity, Inc. (NASDAQ:IVTY) will report earnings of ($0.50) per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Invuity’s earnings. The highest EPS estimate is ($0.48) and the lowest is ($0.54). Invuity posted earnings of ($0.56) per share during the same quarter last year, which would suggest a positive year over year growth rate of 10.7%. The firm is expected to announce its next quarterly earnings report on Tuesday, February 13th.

According to Zacks, analysts expect that Invuity will report full-year earnings of ($2.41) per share for the current year, with EPS estimates ranging from ($2.51) to ($2.32). For the next financial year, analysts anticipate that the company will post earnings of ($1.92) per share, with EPS estimates ranging from ($2.23) to ($1.70). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Invuity.

Invuity (NASDAQ:IVTY) last issued its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported ($0.52) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.04. The firm had revenue of $9.60 million during the quarter, compared to analyst estimates of $9.87 million. Invuity had a negative return on equity of 212.38% and a negative net margin of 111.43%.

A number of research analysts have recently weighed in on IVTY shares. Zacks Investment Research lowered Invuity from a “hold” rating to a “sell” rating in a research report on Thursday, September 28th. Piper Jaffray Companies restated a “buy” rating and set a $12.00 price objective on shares of Invuity in a research report on Friday, November 10th. Finally, Northland Securities restated a “buy” rating and set a $13.00 price objective on shares of Invuity in a research report on Tuesday, September 26th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Invuity has an average rating of “Hold” and an average price target of $11.67.

Invuity (IVTY) opened at $5.60 on Monday. The firm has a market capitalization of $95.98, a PE ratio of -2.27 and a beta of -0.25. The company has a current ratio of 2.90, a quick ratio of 2.47 and a debt-to-equity ratio of 5.39. Invuity has a 12-month low of $5.40 and a 12-month high of $9.70.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IVTY. Citadel Advisors LLC purchased a new position in Invuity in the second quarter worth about $101,000. OxFORD Asset Management LLP purchased a new position in Invuity in the second quarter worth about $374,000. CAPROCK Group Inc. grew its position in Invuity by 28.6% in the third quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 10,000 shares in the last quarter. Royce & Associates LP grew its position in Invuity by 141.9% in the second quarter. Royce & Associates LP now owns 98,939 shares of the medical instruments supplier’s stock worth $717,000 after acquiring an additional 58,033 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC purchased a new position in Invuity in the second quarter worth about $1,549,000. Institutional investors own 69.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “-$0.50 EPS Expected for Invuity, Inc. (IVTY) This Quarter” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/01/15/0-50-eps-expected-for-invuity-inc-ivty-this-quarter.html.

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Get a free copy of the Zacks research report on Invuity (IVTY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Invuity (NASDAQ:IVTY)

Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.